Immatics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United State...
Latest News
6 days ago · zacks.com
Immatics (IMTX) Reports Q3 Loss, Lags Revenue EstimatesImmatics (IMTX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.
6 days ago · globenewswire.com
Immatics Announces Third Quarter 2026 Financial Results and Business UpdateHouston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended September 30, 2026.
8 days ago · zacks.com
Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
24 days ago · globenewswire.com
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingHouston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy.
3 months ago · seekingalpha.com
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaImmatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed TCR therapy in phase 3 SUPRAME for 2nd-line melanoma, with final PFS data expected in H1 2027. Positive phase 1b data [56% cORR, 6.1m PFS] and expansion into metastatic uveal melanoma support label expansion and broader PRAME pipeline ambitions.
3 months ago · globenewswire.com
Immatics Announces $150 Million Underwritten OfferingHouston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant, which represents the per share offering price less the $0.001 per share exercise price for each pre-funded warrant, in an underwritten offering.
3 months ago · globenewswire.com
Immatics Announces Second Quarter 2026 Financial Results and Business UpdateHouston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended June 30, 2026.
5 months ago · seekingalpha.com
Immatics: PRAME Is Becoming More Than A Single-Asset StoryImmatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma, but broader value lies in its layered PRAME franchise and pipeline expansion. IMTX maintains a strong cash runway into 2028, enabling critical clinical milestones without distressed financing or near-term capital risk.
6 months ago · globenewswire.com
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingHouston, Texas and Tuebingen, Germany , June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses.
6 months ago · zacks.com
Immatics (IMTX) Reports Q1 Loss, Lags Revenue EstimatesImmatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.35 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IMTX